FDA Grants ‘Priority Review’ Of Plant-Derived CBD Extract

If Epidiolex achieves FDA-approval, analysts suggest the product could retail for between $30,000 to $60,000 annually.

DISTRICT OF COLUMBIA: Representatives of the US Food and Drug Administration will undertake a ‘priority review‘ of data specific to the safety and efficacy of Epidiolex, a standardized, plant-derived CBD extract formulated by a British pharmaceutical company. The review is scheduled to be completed by June 27, 2018. Phase III clinical trial data shows that Epidiolex Read the full article…

Study: Marijuana Use Linked To Lower Prevalence Of Fatty Liver Disease

"We observed a strong dose-dependent reduction in the prevalence of NAFLD with cannabis use suggesting that cannabis use might suppress or reverse NAFLD development."

MASSACHUSETTS: Subjects who consume cannabis are significantly less likely to suffer from non-alcoholic fatty liver disease (NAFLD) as compared to those who do not, according to population-based case-control data published in the journal PLOS One. Non-alcoholic fatty liver disease is the most prevalent form of liver disease in humans, affecting an estimated 80 to 100 million people in the United States. Read the full article…

Fact: Daily Marijuana Users Are As Healthy As Non-Smokers

“Frequency of marijuana use was not significantly associated with emergency room use, hospitalization, death, the presence of a disease, or health status.”

SWITZERLAND: Cannabis is a “dangerous and addictive” drug, say proponents of ongoing pot prohibition. But daily tokers don’t seem to have higher levels of health problems, emergency department use or hospital stays than people who don’t smoke pot, according to a new study in the Journal of Internal Medicine this month.